ZA200110044B - Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders. - Google Patents

Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders.

Info

Publication number
ZA200110044B
ZA200110044B ZA200110044A ZA200110044A ZA200110044B ZA 200110044 B ZA200110044 B ZA 200110044B ZA 200110044 A ZA200110044 A ZA 200110044A ZA 200110044 A ZA200110044 A ZA 200110044A ZA 200110044 B ZA200110044 B ZA 200110044B
Authority
ZA
South Africa
Prior art keywords
dopamine
receptor ligands
treating kidney
kidney disorders
producing medicaments
Prior art date
Application number
ZA200110044A
Other languages
English (en)
Inventor
Muehlbauer Bernd
Gerhard Gross
Dorothea Starck
Hans-Joerg Treiber
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200110044B publication Critical patent/ZA200110044B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200110044A 1999-05-07 2001-12-06 Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders. ZA200110044B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19922443A DE19922443A1 (de) 1999-05-07 1999-05-07 Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Publications (1)

Publication Number Publication Date
ZA200110044B true ZA200110044B (en) 2003-03-06

Family

ID=7908194

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200110044A ZA200110044B (en) 1999-05-07 2001-12-06 Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders.

Country Status (19)

Country Link
US (2) US7098214B1 (cs)
EP (1) EP1176963B1 (cs)
JP (3) JP4727822B2 (cs)
KR (2) KR100781828B1 (cs)
CN (2) CN1360502B (cs)
AT (1) ATE284693T1 (cs)
AU (1) AU770671B2 (cs)
BR (1) BR0010337A (cs)
CA (1) CA2368823C (cs)
CZ (1) CZ301832B6 (cs)
DE (2) DE19922443A1 (cs)
DK (1) DK1176963T3 (cs)
ES (1) ES2234597T3 (cs)
HU (1) HU228516B1 (cs)
IL (2) IL146232A0 (cs)
NO (1) NO329325B1 (cs)
PT (1) PT1176963E (cs)
WO (1) WO2000067847A2 (cs)
ZA (1) ZA200110044B (cs)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
WO2001024796A1 (en) 1999-10-01 2001-04-12 Smithkline Beecham Corporation 1,2,4-triazole derivatives, composition, process of making and methods of use
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
ES2317116T3 (es) 2001-02-16 2009-04-16 Aventis Pharmaceuticals Inc. Derivados de carbonilos sustituidos heterociclicos y su uso como ligandos del receptor de dopamina d3.
ES2275853T3 (es) * 2001-02-16 2007-06-16 Aventis Pharmaceuticals Inc. Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3.
CA2438318A1 (en) * 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
DE10109867A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10109866A1 (de) * 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
DE10131543A1 (de) * 2001-06-29 2003-01-16 Abbott Lab Pyrimidinoxyalkylpiperazine und ihre therapeutische Verwendung
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
WO2003065871A2 (en) * 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
WO2004082569A2 (en) * 2003-03-17 2004-09-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
MX2007001530A (es) * 2004-08-09 2007-04-23 Abbott Gmbh & Co Kg Compuestos de 4-piperazinil-pirimidina adecuados para tratar trastornos que responde a la modulacion del receptor dopamina d3.
EP2311803A1 (en) 2004-10-14 2011-04-20 Abbott GmbH & Co. KG Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2006040179A1 (en) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
NZ555121A (en) 2004-10-14 2011-01-28 Abbott Gmbh & Co Kg 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine d3 recptor
KR101325519B1 (ko) 2004-10-14 2013-11-08 애보트 게엠베하 운트 콤파니 카게 도파민 ｄ3 수용체의 조절에 반응하는 장애를 치료하기에적합한 아릴설포닐메틸 또는 아릴설폰아미드 치환된 방향족화합물
EP2004166A2 (en) * 2006-03-31 2008-12-24 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
KR20090035581A (ko) * 2006-08-04 2009-04-09 아지노모토 가부시키가이샤 신장 기능 장해 예방ㆍ치료제
JPWO2009093471A1 (ja) * 2008-01-25 2011-05-26 学校法人日本大学 アポトーシス抑制薬
KR20190028281A (ko) 2017-09-08 2019-03-18 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE628766A (cs) * 1962-12-26
US3290004A (en) * 1965-04-09 1966-12-06 Hitachi Ltd Device for damping vibration of long steam-turbine blades
DE4223921A1 (de) 1992-07-21 1994-01-27 Hartmut Prof Dr Med Oswald Herstellung und Verwendung von Hemmstoffen der DOPA-Decarboxylase sowie von Dopamin-Rezeptor-Antagonisten zur Bekämpfung der fortschreitenden Verschlechterung der Nierenfunktion beim Menschen
DE4425143A1 (de) * 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen

Also Published As

Publication number Publication date
WO2000067847A2 (de) 2000-11-16
IL146232A (en) 2007-06-03
JP5897054B2 (ja) 2016-03-30
CN1360502B (zh) 2010-08-04
DE19922443A1 (de) 2000-11-09
CZ20014015A3 (cs) 2002-02-13
NO20015413L (no) 2001-11-15
NO329325B1 (no) 2010-09-27
AU770671B2 (en) 2004-02-26
CA2368823C (en) 2008-10-21
JP2011088941A (ja) 2011-05-06
KR20070040425A (ko) 2007-04-16
NO20015413D0 (no) 2001-11-06
CN1360502A (zh) 2002-07-24
EP1176963A2 (de) 2002-02-06
US7098214B1 (en) 2006-08-29
ATE284693T1 (de) 2005-01-15
CA2368823A1 (en) 2000-11-16
PT1176963E (pt) 2005-05-31
KR20010112474A (ko) 2001-12-20
WO2000067847A3 (de) 2001-08-02
IL146232A0 (en) 2002-07-25
JP2002544178A (ja) 2002-12-24
JP4727822B2 (ja) 2011-07-20
BR0010337A (pt) 2002-02-13
ES2234597T3 (es) 2005-07-01
CZ301832B6 (cs) 2010-07-07
CN101524356A (zh) 2009-09-09
HUP0202399A2 (hu) 2002-12-28
US8785447B2 (en) 2014-07-22
JP2014098044A (ja) 2014-05-29
DK1176963T3 (da) 2005-04-25
EP1176963B1 (de) 2004-12-15
AU4559100A (en) 2000-11-21
HUP0202399A3 (en) 2003-02-28
JP5542713B2 (ja) 2014-07-09
DE50008964D1 (de) 2005-01-20
HU228516B1 (en) 2013-03-28
KR100781828B1 (ko) 2007-12-03
US20060223793A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
ZA200110044B (en) Use of dopamine D receptor ligands for producing medicaments for treating kidney disorders.
BG108495A (en) 5-ht receptor ligands and uses thereof
MXPA03010201A (es) Derivados de 2-piridin-ciclohexan-1,4-diamina sustituidos.
WO1999017755A3 (en) Medicaments
PL1888541T3 (pl) Związki benzo[d]izoksazol-3-iloaminy i ich zastosowanie jako ligandów receptora waniloidowego
MXPA03001483A (es) Heterociclos biciclicos medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
IL210046A0 (en) Ccr1 antagonists for the treatment of i.a. demyelinating inflammatory disease
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
PT1149078E (pt) Ligandos receptores de 5-ht6 selectivos
MXPA03001510A (es) Heterociclos biciclicos, medicamentos que contiene estos compuestos, su empleo y procedimientos para su preparacion.
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
GB9716879D0 (en) Treatment of attention deficit disorders
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
WO2003039539A3 (de) Verwendung von endothelin-rezeptor-antagonisten zur behandlung von tumorerkrankungen
WO2001049654A3 (de) Substituierte aminomethyl-phenyl-cyclohexanderivate
AU2002358469A8 (en) Modified receptors for the discovery of therapeutic ligands
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
CY2456B1 (en) At1 receptor antagonist for the stimulation of apoptosis.
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
MXPA03001472A (es) Compuestos para el tratamiento de trastornos adictivos.
MY127328A (en) 5-amino-1-pentene-3-ol substituted derivatives
AU2001278549A1 (en) Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors
TNSN07291A1 (en) Use of a pyrazole derivative for preparing medicines useful for preventing or treating renal diseases
UA87292C2 (ru) Применение сирамезина для лечения злокачественных опухолей
TW200407314A (en) Preparation of 4, 6-dichloro-5-fluoropyrimidine